Precision Matters: PEGylation and Glycosylation as Critical Tools in Bioconjugation for Drug Development

This webinar offers an in-depth exploration of advanced bioconjugation strategies.

23

September

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

This webinar provides an in-depth exploration of advanced bioconjugation strategies, starting with a concise overview of covalently linking biomolecules to synthetic compounds. It delves into targeted conjugation chemistries using natural amino acid residues and explores alternative methods like glycoPEGylation, with a focus on optimizing reaction conditions to achieve desired specificity and higher yield. The program also highlights the development of conjugate vaccines, particularly the use of carrier proteins, to enhance immune responses, and showcases the need for integrated manufacturing capabilities, including GMP-compliant production and analytical method development. Additionally, it addresses the strategies and challenges of carbohydrate conjugation, and concludes with an exploration of both established and emerging techniques in peptide conjugation.

Learning Objectives:

  • Compare and evaluate bioconjugation strategies, including approaches targeting natural amino acid residues and alternative methods such as glycoPEGylation, while understanding critical parameters like reagent ratios, pH and temperature for optimizing reaction efficiency and specificity.
  • Describe the rationale and techniques for carbohydrate conjugation, distinguishing between reducing and nonreducing terminus strategies, and comparing total synthesis approaches with conjugation of native (unprotected) oligosaccharides.
  • Explain the principles of conjugate vaccine development, focusing on how carbohydrates and poorly immunogenic antigens are chemically linked to carrier proteins to enhance immune responses, and recognize the unique challenges involved in carbohydrate conjugation.

Speakers

Select a speaker to learn more

Back
Dr Scott Miller
Senior Director of R&D

Scott Miller, is our new Senior Director of R&D. Scott brings experience from previous roles at CARBOGEN AMCIS AG, Adolor Corporation, Cephalon and Hovione. He holds a 1990 - 1992 Postdoctoral Fellow in Chemistry from ETH Zürich. Scott boasts a robust skill set that includes project management, cGMP manufacturing, chemistry process research and development from preclinical through validation, as well as CMC IND, ANDA, and NDA filings.

Next speaker
Back
Dr Hans Streicher
Scientific Advisor

Hansjoerg Streicher studied organic chemistry at the University of Konstanz, Germany, with a focus on carbohydrates, glycoscience, and synthesis. After a period as a visiting scientist at the Weizmann Institute of Science, Israel, he became a Lecturer in Chemistry and Chemical Biology at the University of Sussex, where he taught and conducted research for eight years. Hans later moved into consultancy, providing expertise in synthetic chemistry and intellectual property before joining Biosynth as a Senior Scientific Advisor. His work supports project teams in glycoscience and organic synthesis, where he continues to contribute to technical marketing and research initiatives.

Next speaker
Back
Dr Julia Wittmann
Bioconjugation Manager

Julia Wittmann holds a diploma in Biology from Georg-August-Universität Göttingen, specializing in Genetics, Microbiology, and Physical Chemistry. Her diploma thesis focused on the molecular biological construction and analysis of a chimeric protein in E. coli. She completed her Ph.D. at the same institution, with research on the targeted modification and binding properties of proteins from

Escherichia coli and Saccharomyces cerevisiae. Since 2003, Dr. Wittmann has served as a scientific researcher in the Department of Molecular Structural Biology at the Institute for Microbiology and Genetics, within Dr. Markus Rudolph's group. Her background also includes experience in a medical analysis laboratory and scientific consulting, encompassing patent research and market analysis.

Next speaker
Back
Dr Laurent Caron
Peptide Market Development Specialist

Laurent's career, grounded in organic chemistry, shifted to peptide synthesis during his 2005 postdoctoral work in Manchester. He joined Cambridge Research Biochemicals, later acquired by Biosynth, as a peptide chemist, gaining hands-on experience in synthesis, purification, and dye-labelling.

Progressing over 17 years, he advanced to managing peptide chemists and production, ultimately becoming a Site Manager and Operational lead, driving scientific development with a focus on novel peptide synthesis methodologies. Laurent now serves as Biosynth's Market Development Specialist for Peptides, a pivotal role in expanding the company's custom and GMP peptide business. He is instrumental in optimizing the project portfolio and enhancing Biosynth's technical and commercial offerings to meet strategic financial and commercial objectives.

Next speaker
Back
Jasper Morley
Drugs Intelligence Analyst at GlobalData

Jasper Morley, senior Drugs Intelligence Analyst at GlobalData. His primary responsibilities include managing and maintaining GlobalData's Drugs Database, analyzing marketed drug information, and producing analytical market insight reports. In addition, Jasper provides timely client support and performs database quality checks. Prior to joining GlobalData, Jasper worked as a Medical Affairs associate at Merz Pharma UK, focusing on Medical Information and Pharmacovigilance activities within the neurology and dermatology therapy areas. More recently, Jasper was employed by the University College London Hospitals NHS Foundation Trust, working within the research facilities of the Cancer Clinical Trials Unit.

Next speaker

Enquiry